Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.

Zhang W, Zhang D, Stashko MA, DeRyckere D, Hunter D, Kireev D, Miley MJ, Cummings C, Lee M, Norris-Drouin J, Stewart WM, Sather S, Zhou Y, Kirkpatrick G, Machius M, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X.

J Med Chem. 2013 Dec 12;56(23):9683-92. doi: 10.1021/jm401387j. Epub 2013 Nov 20. Erratum in: J Med Chem. 2014 Aug 28;57(16):7141.

PMID:
24195762
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

Zhang W, McIver AL, Stashko MA, DeRyckere D, Branchford BR, Hunter D, Kireev D, Miley MJ, Norris-Drouin J, Stewart WM, Lee M, Sather S, Zhou Y, Di Paola JA, Machius M, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X.

J Med Chem. 2013 Dec 12;56(23):9693-700. doi: 10.1021/jm4013888. Epub 2013 Nov 20.

PMID:
24219778
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

UNC1062, a new and potent Mer inhibitor.

Liu J, Zhang W, Stashko MA, Deryckere D, Cummings CT, Hunter D, Yang C, Jayakody CN, Cheng N, Simpson C, Norris-Drouin J, Sather S, Kireev D, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X.

Eur J Med Chem. 2013 Jul;65:83-93. doi: 10.1016/j.ejmech.2013.03.035. Epub 2013 Apr 2.

PMID:
23693152
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.

Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, Janzen WP, Johnson GL, Wang X, Frye SV, Earp HS 3rd, Graham DK.

Mol Cancer Ther. 2013 Nov;12(11):2367-77. doi: 10.1158/1535-7163.MCT-13-0040. Epub 2013 Aug 30.

PMID:
23997116
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Identification of novel, potent and selective inhibitors of Polo-like kinase 1.

Chen S, Bartkovitz D, Cai J, Chen Y, Chen Z, Chu XJ, Le K, Le NT, Luk KC, Mischke S, Naderi-Oboodi G, Boylan JF, Nevins T, Qing W, Chen Y, Wovkulich PM.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1247-50. doi: 10.1016/j.bmcl.2011.11.052. Epub 2011 Dec 1.

PMID:
22172702
[PubMed - indexed for MEDLINE]
6.

Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents.

Lukasik PM, Elabar S, Lam F, Shao H, Liu X, Abbas AY, Wang S.

Eur J Med Chem. 2012 Nov;57:311-22. doi: 10.1016/j.ejmech.2012.09.034. Epub 2012 Oct 3.

PMID:
23085105
[PubMed - indexed for MEDLINE]
7.

Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.

Park BS, El-Deeb IM, Yoo KH, Oh CH, Cho SJ, Han DK, Lee HS, Lee JY, Lee SH.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4720-3. doi: 10.1016/j.bmcl.2009.06.066. Epub 2009 Jun 21.

PMID:
19596575
[PubMed - indexed for MEDLINE]
8.

Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.

Gangjee A, Namjoshi OA, Yu J, Ihnat MA, Thorpe JE, Warnke LA.

Bioorg Med Chem. 2008 May 15;16(10):5514-28. doi: 10.1016/j.bmc.2008.04.019. Epub 2008 Apr 14.

PMID:
18467105
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.

Zhang X, Raghavan S, Ihnat M, Thorpe JE, Disch BC, Bastian A, Bailey-Downs LC, Dybdal-Hargreaves NF, Rohena CC, Hamel E, Mooberry SL, Gangjee A.

Bioorg Med Chem. 2014 Jul 15;22(14):3753-72. doi: 10.1016/j.bmc.2014.04.049. Epub 2014 May 14.

PMID:
24890652
[PubMed - indexed for MEDLINE]
10.

Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.

Finlay MR, Buttar D, Critchlow SE, Dishington AP, Fillery SM, Fisher E, Glossop SC, Graham MA, Johnson T, Lamont GM, Mutton S, Perkins P, Pike KG, Slater AM.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4163-8. doi: 10.1016/j.bmcl.2012.04.036. Epub 2012 Apr 13.

PMID:
22607682
[PubMed - indexed for MEDLINE]
11.

Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.

Sato Y, Onozaki Y, Sugimoto T, Kurihara H, Kamijo K, Kadowaki C, Tsujino T, Watanabe A, Otsuki S, Mitsuya M, Iida M, Haze K, Machida T, Nakatsuru Y, Komatani H, Kotani H, Iwasawa Y.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4673-8. doi: 10.1016/j.bmcl.2009.06.084. Epub 2009 Jun 25.

PMID:
19589677
[PubMed - indexed for MEDLINE]
12.

Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.

Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H, Buchdunger E, Meyer T, Mueller M, Furet P.

J Med Chem. 1997 Oct 24;40(22):3601-16.

PMID:
9357527
[PubMed - indexed for MEDLINE]
13.

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.

Linger RM, Keating AK, Earp HS, Graham DK.

Expert Opin Ther Targets. 2010 Oct;14(10):1073-90. doi: 10.1517/14728222.2010.515980. Review.

PMID:
20809868
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T, Brodfuehrer J, Choi C, Barvian MR, Fry DW.

J Med Chem. 2005 Apr 7;48(7):2388-406.

PMID:
15801831
[PubMed - indexed for MEDLINE]
15.

Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.

Li Q, Woods KW, Thomas S, Zhu GD, Packard G, Fisher J, Li T, Gong J, Dinges J, Song X, Abrams J, Luo Y, Johnson EF, Shi Y, Liu X, Klinghofer V, Des Jong R, Oltersdorf T, Stoll VS, Jakob CG, Rosenberg SH, Giranda VL.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):2000-7. Epub 2006 Jan 18.

PMID:
16413780
[PubMed - indexed for MEDLINE]
16.

Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.

Claridge S, Raeppel F, Granger MC, Bernstein N, Saavedra O, Zhan L, Llewellyn D, Wahhab A, Deziel R, Rahil J, Beaulieu N, Nguyen H, Dupont I, Barsalou A, Beaulieu C, Chute I, Gravel S, Robert MF, Lefebvre S, Dubay M, Pascal R, Gillespie J, Jin Z, Wang J, Besterman JM, MacLeod AR, Vaisburg A.

Bioorg Med Chem Lett. 2008 May 1;18(9):2793-8. doi: 10.1016/j.bmcl.2008.04.009. Epub 2008 Apr 9.

PMID:
18434145
[PubMed - indexed for MEDLINE]
17.

Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors.

Mao Y, Zhu W, Kong X, Wang Z, Xie H, Ding J, Terrett NK, Shen J, Shen J.

Bioorg Med Chem. 2013 Jun 1;21(11):3090-104. doi: 10.1016/j.bmc.2013.03.053. Epub 2013 Apr 1.

PMID:
23602524
[PubMed - indexed for MEDLINE]
18.
19.

Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors.

El-Deeb IM, Park BS, Jung SJ, Yoo KH, Oh CH, Cho SJ, Han DK, Lee JY, Lee SH.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5622-6. doi: 10.1016/j.bmcl.2009.08.029. Epub 2009 Aug 12.

PMID:
19700314
[PubMed - indexed for MEDLINE]
20.

Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.

Sleebs BE, Nikolakopoulos G, Street IP, Falk H, Baell JB.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5992-4. doi: 10.1016/j.bmcl.2011.07.050. Epub 2011 Jul 23. Erratum in: Bioorg Med Chem Lett. 2012 Jan 1;22(1):755-7.

PMID:
21852129
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk